Asparaginase
- PDF / 141,236 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 118 Downloads / 143 Views
1
S
Pancreatitis in children: 3 case reports Three children developed pancreatitis during treatment with asparaginase for B-precursor acute lymphoblastic leukaemia [routes and dosages not stated; durations of treatment to reaction onset not clearly stated]. A 4-year-old boy developed NCI-CTCAE grade 3 pancreatitis during induction therapy with asparaginase. Two months after the onset of his pancreatitis, he was administered asparaginase 6000 ku/m2 x 6/2w sc. On this occasion, he also received octreotide. Laboratory and clinical tests showed no pancreatitis. An 8-year-old girl developed NCI-CTCAE grade 2 pancreatitis during maintenance therapy with asparaginase. Twenty-two months after the onset of her pancreatitis, she was administered asparaginase 10 000 ku/m2 x 1 sc. On this occasion, she also received octreotide. Laboratory and clinical tests showed no pancreatitis. A 10-year-old boy developed NCI-CTCAE grade 2 pancreatitis during induction therapy with asparaginase. Fifteen months after the onset of his pancreatitis, he was administered asparaginase 6000 ku/m2 x 6/2w sc. On this occasion, he also received octreotide. Laboratory and clinical tests showed no pancreatitis. Tokimasa S, et al. Does octreotide prevent l-asparaginase-associated pancreatitis in children with acute lymphoblastic leukaemia?. British Journal of Haematology 157: 381-382, No. 3, May 2012. Available from: URL: http://dx.doi.org/10.1111/ 803072281 j.1365-2141.2011.08971.x - Japan
0114-9954/10/1407-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Reactions 23 Jun 2012 No. 1407
Data Loading...
